Excerpt:“… The clinical data for the drug ivonescimab — also known as AK112 — missed expectations, analyst Criss Wang wrote in a note on SMARTKARMA. “The high valuation of Akeso has already priced in the success of AK112, which if it fails in critical clinical trials,…”
BN (Bloomberg News)via Bloomberg • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
BN (Bloomberg News)
